The Influence of Long-term Diabetes Mellitus on Pain Response in Mice: In Vivo Models of Painful Diabetic Neuropathy (PDN) by Fajrin, Fifteen Aprila et al.
97
Fajrin FA et al., The influence of long-term diabetes mellitus (DM) on pain response 
in mice: in vivo models of painful diabetic neuropathy (PDN)
Corresponding author: fiezz_15@yahoo.co.id
J Med Sci, Volume 49, No. 3, 2017 July: 97-105
Optimization of  Mice Model of Painful 
Diabetic Neuropathy (PDN)
Fajrin FA1,2*,  Nurrochmad A3, Nugroho AE3, Susilowati R4
1Postgraduate Programme, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 
2Department of Clinical and Community Pharmacy, Faculty of Pharmacy, Jember 
University, Jember, 3Department of Pharmacology and Clinical Pharmacy, Faculty of 
Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia, 4Department of Histology 
and Cell Biology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta.
DOI: http://dx.doi.org/10.19106/JMedSci004903201701
ABSTRACT
Painful diabetic neuropathy (PDN) is a complication of long-term diabetes mellitus (DM) 
characterized by hyperalgesia and allodynia. In streptozotocin (STZ)-induced diabetic 
mice, higher dose of STZ and lengthened hyperglycemic condition results in better model 
of PDN. However, higher dose of STZ tend to induce mortality. The aim of the study was 
to evaluate the doses of STZ that caused PDN with less mortality rate and the timing 
of pain behavior development in mice model of PDN. BALB/c mice were divided into 
non-diabetic and STZ-induced diabetic group. The doses of STZ were started from 180 
mg/kg BW i.p. Serum glucose levels were measured 7 days (one week) after induction. 
Mice with glucose levels ≥ 200 mg/dL were considered as diabetic. Pain behaviour was 
determined by four method i.e. hot plate, tail flick, von Frey filament and Randall Selitto 
tests, measured on week-0 (baseline), 1, 2, 3, 4 and 5. Data were presented as mean 
± SEM. The mean differences between weeks were evaluated by One-Way ANOVA and 
the mean differences between two groups by independent t-test. STZ doses 180, 150 
and 120 mg/kg BW caused 100% death and STZ 90 mg/kg BW failed to induce diabetic 
condition. STZ 110 mg/kg BW resulted in 0% mortality while it induced diabetes in 100% 
of the mice. Latency time toward thermal stimulus decreased to 5.8 ± 0.4 sec at 1st 
week after the mice become diabetes (p<0.05) and it was continued to decrease until 
4th week. The same result was also showed in tail flick and Randal Selitto tests. The 
pain sensitivity determined by von Frey filament decreased to 1.37 ± 0.12 g at 1st week 
(p<0.05) and continued to decrease until 5th week. In conclusion, optimum dose of STZ 
to induce PDN was 110 mg/kg BW. Pain behaviour of diabetic group was observed at 1st 
week after diabetes and continued until 5th week.
ABSTRAK
Nyeri neuropati diabetes (NND) adalah salah satu komplikasi diabetes melitus (DM) 
jangka panjang yang ditandai dengan hyperalgesia dan alodinia. Pada mencit diabetes 
yang diinduksi streptozotosin (STZ), dosis tinggi STZ dan kondisi hiperglikemia yang 
berkepanjangan menghasilkan model NND yang lebih baik. Akan tetapi dosis tinggi STZ 
cenderung menyebabkan kematian. Penelitian ini bertujuan untuk mengkaji dosis STZ 
yang menyebabkan NND dengan tingkat kematian rendah dan waktu timbulnya rasa nyeri 
pada model mencit NND. Mencit BALB/c dibagi menjadi kelompok tikus tidak DM dan 
tikus DM akibat induksi STZ. Dosis STZ dimulai dengan 180 mg/kg BB yang diberikan 
secara intraperitonial. Kadar gula darah diukur 7 hari (satu minggu) setelah induksi. Mencit 
dengan kadar gula darah ≥ 200 mg/dL ditetapkan sebagai mencit DM.  Perilaku nyeri 
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ditetapkan menggunakan 4 metode yaitu metode hot plate, tail flick, von Frey filament 
dan Randall Selitto yang diukur pada minggu ke 0 (data awal), 1, 2, 3, 4 dan 5. Data 
disajikan sebagai rerata ± SEM. Perbedaan rerata antara perilaku nyeri setiap minggu 
dievaluasi dengan ANOVA satu jalan dan perbedaan antara 2 kelompok dievaluasi dengan 
uji t. Dosis STZ 180, 150 dan 120 mg/kg BB menyebabkan 100% kematian dan dosis 
STZ 90 mg/kg BW gagal menginduksi diabetes. Dosis STZ 110 mg/kgBB menghasil 0% 
kematian dan menginduksi diabetes 100% mencit. Waktu latensi terhadap stimulus panas 
menurun 5,8 ± 0,4 detik pada minggu pertama setelah mencit diabetes (p<0,05) dan 
berlanjut menurun hingga minggu ke 4. Hasil yang sama juga ditunjukkan pada uji dengan 
tail fick dan Randal Selitto. Sensitivitas nyeri yang diukur dengan von Frey filament 
menurun menjadi 1,37 ± 0,12 g pada minggu pertama (p<0,05) dan berlanjut menurun 
hingga minggu ke 5. Dosis optimum STZ untuk menginduksi NND adalah 110 mg/kg BB. 
Perilaku nyeri kelompok diabetes teramati pada minggu pertama setelah diabetes dan 
berlanjut hingga minggu ke 5. 
Keywords: Painful diabetic neuropathy, hot plate, tail flick test, von Frey filament, Randall 
Selitto
INTRODUCTION
Diabetes mellitus (DM) is the leading 
cause of degenerative diseases with the highest 
mortality rate.1 Diabetes mellitus is caused by 
disturbance in insulin secretion, insulin action, 
or both that characterized by hyperglycemia.2 
Hyperglycemia and reduce cellular source of 
energy lead to many complication of diabetes. 
Painful Diabetic Neuropathy (PDN) is the 
most common complication of diabetes, occurs 
in 25-50% diabetic patients, as a result of 
abnormal pain signal system due to peripheral 
nerves damage.3 Patient with PDN usually 
complains chronic pain with hyperalgesia 
and allodynia, which interfere their daily 
activities.4 Therefore, the prevention of PDN 
development in diabetic patients are crucial in 
maintaining the patient’s quality of life.3,4
For the purpose of drug development, 
animal model of PDN is needed. One of the 
most common animal model is Streptozotocin 
(STZ)-induced diabetic mice. From the 
literature, the doses of STZ used for diabetic 
induction in mice are varied.5,6,7,8 Higher dose 
may induce lethal hyperglycemia that may 
prevent complete measurement and analysis. 
An appropriate dose of STZ is important, 
balancing the need to induce hyperglycemia 
and PDN, while at the same time reducing 
animal mortality rate.
PDN state occurs as early as 2-4 weeks 
after establishment of hyperglicemia. 
Prolonged hyperglicemia at more than six 
weeks caused hypoalgesia, related to loss of 
nerves fibers.9 Several studies reported more 
than four weeks of hyperglicemia is needed 
to develop PDN in mice.7,10,11 However, 
prolonged hyperglycemia increases diabetic 
mice mortality rate. With many animals died, 
the purpose of investigation won’t be fulfilled. 
Therefore, it is important to evaluate the doses 
of STZ that induce PDN with less mortality 
rate in mice. The timing of pain behavior 
development in mice model of PDN also 
needs to be investigated.
MATERIALS AND METHODS
Materials 
All the reagents and chemical used 
for this research were analytical grade. 
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Streptozotocin was purchased from Biolab 
(USA), Biochemical diagnostic such as 
glucose oxidase – glucose peroxidase 
(GOD-POD) kit was purchased from DyaSis 
(Germany) and citrate buffer pH 4.5 was from 
Sigma (Singapore). The pain behavior was 
determined using hot plate (UgoBasile, Italy), 
tail flick test (Columbus Instrument, USA), 
von Frey filament (Aesthesio, USA) and 
Randall Selitto (UgoBasile, Italy).
Preparation of STZ
Streptozotocin 1.1% was dissolved in 
freshly prepared ice cold citrate buffer (pH 
4.5) before used. 
Preparation of experimental animals
Fourty-three of male BALB/c strain mice 
(25-35 g, 8-10 w) were obtained from Faculty 
of Pharmacy, Gadjah Mada University, 
Yogyakarta, Indonesia. Mice were placed in 
clean cages and maintained at temperature 
25±1 °C with 12 hours light/dark cycle. 
Mice had free access on food and water 
ad libitum. Ethical clearance was obtained 
from the Medical and Health Research Ethic 
Committee, Faculty of Medicine, Universitas 
Gadjah Mada-Dr. Sardjito General Hospital, 
Yogyakarta number Ref. KE/FK/559/
EC/2016.
Experimental protocol
Mice were fasted overnight for 12 hours, 
before the experiment. Each group of mice 
were given a single-high-dose of STZ (180, 
150, 120, 110 or 90 mg/kg BW) i.p. The 
fasting-blood glucose levels were checked 
7 days after STZ induction using GOD-
POD kit. Mice with fasting-blood glucose 
levels ≥200 mg/dL were considered diabetes. 
Measurement of blood glucose levels were 
conducted once every week until week 5.
Pain behavioral assays
Pain behavior assays were measured 
before STZ induction and at week 1, 2, 3, 4 
and 5 after diabetes. All experiments were 
taken in three replications.
Hot plate test
Each mouse was placed individually on a 
hot plate that adjusted at 50±0.5°C. The latency 
time toward thermal stimulus was evaluated 
when the mice showed pain responses such as 
licking, jumping, tapping, rearing, flattering 
and frizzing (whatever which came first). 
The cut off time was 30 sec in order to avoid 
damage of the nerves.12,13
Tail flick test
The tail of each mouse was exposed to 
nichrome-radiant heat. The intensity of the 
radiant heat was adjusted to give a basal 
latency of 6-8 sec in both diabetic and non-
diabetic groups. Tail flick latency was time 
interval that taken by mice to flick its tail after 
the exposure of radiant heat. The maximum 
cut-off time was 15 sec to prevent tissue 
damage.14,15 
von Frey filament test
The sensitivity of mechanical stimulus 
was measured by von Frey filament. Mice 
were placed in an individual glass-caged that 
completed by wire-mesh-bottom. A von Frey 
filament was applied 10 times for 5 sec to the 
foot pads of the hind paw and the number of 
positive response (such as jumping, scratching 
or scraping) was recorded. The increasing of 
sensitivity was interpreted as more than 5 
positive responses from 10 times test.12,13
Randall Selitto test
Randall Selitto test applied pressure to 
the dorsal surface of the hind paws via conical 
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TABLE 1. The percentage of diabetic mice and mortality in various doses of STZ induction until 5 weeks
Dose
(mg/kg BW)
n DM+ Number of mortality at week Total mortality
n % 0 1 2 3 4 5 n %
180* 6 3 50 3 1  0  0 1 0 5 83.30
150 7 7 100 0 2 1 0 0 0 3 42.86
120 4 4 100 0 1 1 1 0 0 3 75
110 8 8 100 0 0 0 0 0 0 0 0
90 10 0 0  0 0 0  0 0  0 0 0
* 3 mice died before the first examination of blood glucose level
          
probe with 250 g cut-off. The pressure was 
increased until the mouse withdrew the paw, 
squeaked or struggled.12,13 
Statistical analysis
Data was statistically analyzed using 
SPSS version 20. All values were described 
as mean ± SEM. The mean differences of 
pain behaviour measurement between weeks 
were compared using One-Way ANOVA 
and between two groups (diabetic and non-
diabetic) using independent t-test. The 
significance level were set at 95%. 
RESULTS
The result of the diabetic induction 
and subsequent survival of the mice after 
administration different dose of STZ was 
presented in TABLE 1. At day 7 after STZ 
administration, doses 180, 150, 120 and 
110 mg/kg BW resulted in 100% diabetic 
induction. Lower STZ dose at 90 mg/kg 
BW failed to induce diabetic condition in 
any mice. Although STZ dose 180, 150 and 
120 mg/kg BW were successful in inducing 
diabetes, the mice survival was a problem. 
Most of the mice were died before week 3 and 
all of the mice from 180 and 120 mg/kg BW 
groups were died at week 7. The mean blood 
glucose level of the died mice at week 1 were 
378.77±74.45 mg/dL, higher than the mean 
of blood glucose level of the surviving mice 
(281.64±66.84 mg/dL). However, it was not 
significantly different (p >0.05). 
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TABLE 2. Pain behaviour assessment in non-diabetic and diabetic groups after STZ induction 
dose 110 mg/kg BW.
Test Groups (n=8) Week-0 1 2 3 4 5
Hot plate 
(sec±SEM)
Non-diabetic 
10.5±
0.2a
10.6±
0.4a#
11.6±
0.4a#
10.3±
0.2a#
11.0±
0.2a#
10.0±
0.2a#
Diabetic 
10.3±
0.3a
5.8±
0.4b##
4.9±
0.3b##
3.9±
0.3b##
3.3±
0.3b##
4.6±
0.4b##
Tail flick 
(sec±SEM)
Non-diabetic 
8.11±
0.12a
7.88±
0.22a#
8.02±
0.07a#
8.19±
0.18a#
8.36±
0.24a#
7.97±
0.25a#
Diabetic 
7.95±
0.18a
5.04±
0.25b##
3.68±
0.24b##
2.66±
0.23b##
2.04±
0.08b##
3.06±
0.14b##
Randall selitto 
(g±SEM)
Non-diabetic 
94.16±
4.21a
88.96±
2.25a#
95.63±
0.83a#
91.88±
1.62a#
90.21±
2.62a#
92.5±
2.52a#
Diabetic 
97.29±
3.55a
53.75±
4.66b##
24.58±
2.50b##
15.83±
2.29b##
11.04±
1.41b##
17.08±
1.43b##
von Frey fila-
ment (g±SEM)
Non-diabetic 
8.79±
0.48a
8.58±
0.29a#
8.91±
0.31a#
8.71±
0.52a#
8.50±
0.33a#
9.08±
0.72a#
Diabetic 
9.33±
0.62a
1.37±
0.12b##
0.67±
0.05b##
0.36±
0.04b##
0.10±
0.01b##
0.10±
0.02b##
Data analysis between groups using independent t test.
a indicated significant differences (p<0.05) of pain behaviour between diabetic and non-diabetic groups of each day of 
measurement.     
#  indicated significant differences (p<0.05) compared to baseline (week-0).           
A B
FIGURE 1. A. Blood glucose levels between diabetic and non-diabetic groups at weeks-0 (baseline), 1, 4 and 5; # 
indicated significant differences compared to non-diabetic group. B. The body weight of diabetic and 
non-diabetic groups at weeks-0 (baseline), 1, 2, 3, 4 and 5
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Pain behaviour in mice were evaluated 
using four different methods. Hyperalgesia 
was determined by hot plate, tail flick and 
Randall Selitto tests Allodynia was determined 
by von Frey filament. The pain behaviour of 
diabetic mice and control mice were described 
in TABLE 2. Diabetic mice shortened latency 
time toward thermal stimulus using hot plate 
from 10.3 sec at baseline to 5.8 sec in the first 
week after STZ induction and lasted up fourth 
week with consecutive latency time 4.9, 3.9, 
and 3.3 sec. This result was significantly 
different with non-diabetic group, which 
maintained the latency time arround 10 sec 
(p<0.05). At week-5, latency time toward 
thermal stimulus become 4.6 sec, longer than 
previous week but still significantly lower 
(p<0.05) than non-diabetic group and not 
returned yet to baseline. 
The pain behavior evaluation using other 
tests such as tail flick and Randall Selitto 
gave similar results. Tail latency time using 
tail flick test shortened from 7.95 s to 5.04 at 
week-1 after STZ induction. This condition 
lasted up 4th week. Decreasing of withdrawal 
load threshold using Randall Selitto test was 
observed from 97.29 g at baseline to 53.75 g 
at week-1 after STZ induction and had been 
reducing until week-4. At the end of the study 
(week-5), the pain responses were less severe 
than the previous week. 
Measurement of pain behaviour using 
von Frey filament showed slightly different 
outcome. The tactile sensitivity towards 
mechanical stimulus was continuously 
decreased until 5th week from 9.33±0.62 g to 
1.37 ± 0.12 g, 0.67 ± 0.05 g, 0.36 ± 0.04 g, 0.10 
± 0.01 g and 0.10 ± 0.02 g and significantly 
different with non-diabetic group (p<0.05).
DISCUSSION
In this study, the dose of STZ 110 mg/
kg BW was found to be the most effective 
in inducing diabetic state while preventing 
mortality of the mice. The STZ dose was 
lower than previous report  i.e. 150 mg/kg, 
180 mg/kg and 200 mg/kg.5,6,8 Administration 
of higher dose of STZ induced higher level 
of blood glucose more than 450 mg/dl. In our 
study, mouse with blood glucose levels up to 
450 mg/dl was more vulnerable to die. When 
we used STZ dose 110 mg/kg BW, the blood 
glucose level was found in the range of 231.89 
until 413.96 mg/dL (mean 281.64±66.84 mg/
dL). Our result was slightly similar to the 
report by Hayashi et al. (2006).16 Their study 
showed that dose 100 and 125 mg/kg BW of 
STZ induced non-insulin dependent diabetes 
in BALB/c mice model and showed a slowly 
progressive diabetic state until 12 weeks.16 
However, our result showed significantly 
increasing of high glucose level in the 
beginning of the study. The glucose levels 
continued to increase until week 5, more than 
the threshold (200 mg/dL).
Animal gender and strain may influence 
the response after STZ induction. Male 
pancreatic islet ß-cells are more prone than 
female cells to STZ-induced toxicity, that 
is why male rodent is more popular for 
diabetic study. Different strain of animals also 
display different sensitivity to STZ. Based 
on Cardinal et al (1998),17 the action of STZ 
in ß-cells varies in different strain due to 
differences in the uptake or metabolism of 
the drug, the rate of DNA repair, the activity 
of Poly (ADP-ribose) polymerase (PARP) or 
damage to Nicotinamide adenine dinucleotide 
(NAD+)-generating mechanism.17 CD-1 and 
C57BL/6 mice were reliably sensitive to STZ, 
while, there was a report that BALB/c mice 
are resistant to multiple low doses of STZ-
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state and this condition continued until 10-11 
weeks.15 
Based on our result, hyperalgesia and 
allodynia in diabetic condition occured at 
the same time (Figure 2). Thermal stimulus-
induced hyperalgesia started in the early 
phases of diabetic condition until week 4. 
There was a trend of reducing hyperalgesia 
in week 5, suggested failure to report the 
stimulus to the central nervous system due 
to severe nerve fibers damage. Mechanical 
stimulus-induced allodynia also occurred at 
the early phases of diabetic condition and 
continues until week 5.  Hyperalgesia usually 
implicates the damage of C and A∂ nerve 
fiber, but in allodynia, Aß nerve fibers are also 
involved.21 The smaller diameter and non-
myelinated nature of C-fibers require higher 
energy consumption, hence more prone to the 
diabetic condition.21 Furthermore, C and A∂ 
nerve fibers contain a lot of TRPV1 molecules 
that are responsible to early hyperalgesia and 
advanced hypoalgesia.22 
FIGURE 2. Development of hyperalgesia, tested with hot plate in sec-
on units (dotted line) and B. allodynia, tested by von Frey 
filaments in g units (straight line) in BALB/c Mice after a 
singe-dose 110 mg/kgBW of STZ-induced PDN.
induced diabetes mellitus.18  In this study, we 
showed that BALB/c mice could be used as 
STZ-induce diabetic animal model. 
At week-0 (baseline), there were no 
pain behavior found in all groups. One week 
after STZ induction, the latency time toward 
thermal stimulus using hot plate and tail flick 
test declined in the hyperglycemia group 
compared to the baseline and the control 
group, supporting previous studies.13,14,19 
According to Saikh and Somani (2010),9 
mechanical hyperalgesia  and tactile allodynia 
occur within 1-8 weeks after STZ induction.9 
In this study, both of mechanical hyperalgesia 
tested by Randall Selitto and tactile allodynia 
tested by von Frey filament were developed 
one week after STZ induction. This result was 
faster compared to other report that showed 
the occurance of mechanical hyperalgesia and 
tactile allodynia in mice model of PDN varies 
within 1-8 weeks after STZ induction.15,19,23-26 
The report from Sugimoto et al. (2013)15 
showed that mechanical hyperalgesia was 
started to be observed at 6th week  after diabetic 
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